

# CITATION REPORT

List of articles citing

**Incidence and determinants of sildenafil  
(dis)continuation: the Dutch cohort of sildenafil users**

**DOI: 10.1038/sj.ijir.3900883**

**International Journal of Impotence Research, 2002, 14, 259-60**

**Source:** <https://exaly.com/paper-pdf/34724400/citation-report.pdf>

**Version:** 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
74	[Therapy of erectile dysfunction in 2005]. <i>Der Urologe</i> , <b>2003</b> , 42, 1330-6		3
73	Some wider opportunities for men with erectile dysfunction. <i>Sexual and Relationship Therapy</i> , <b>2003</b> , 18, 5-6	1.1	3
72	Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference. <i>Clinical Therapeutics</i> , <b>2003</b> , 25, 2724-37	3.5	66
71	Review of tadalafil in the treatment of erectile dysfunction. <i>Expert Opinion on Pharmacotherapy</i> , <b>2003</b> , 4, 2049-56	4	16
70	Erectile response with vardenafil in sildenafil nonresponders: a multicentre, double-blind, 12-week, flexible-dose, placebo-controlled erectile dysfunction clinical trial. <i>BJU International</i> , <b>2004</b> , 94, 1301-9	5.6	59
69	Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. <i>International Journal of Impotence Research</i> , <b>2004</b> , 16, 135-42	2.3	67
68	Clinical evaluation and management strategy for sexual dysfunction in men and women. <i>Journal of Sexual Medicine</i> , <b>2004</b> , 1, 49-57	1.1	134
67	The efficacy and safety of flexible-dose vardenafil (levitra) in a broad population of European men. <i>European Urology</i> , <b>2004</b> , 45, 634-41; discussion 641	10.2	66
66	[Erectile dysfunction. New drugs with special consideration of the PDE 5 inhibitors]. <i>Der Urologe</i> , <b>2004</b> , 43, 820-8		9
65	Sildenafil failures may be due to inadequate patient instructions and follow-up: a study on 100 non-responders. <i>European Urology</i> , <b>2005</b> , 47, 518-22; discussion 522-3	10.2	68
64	Flexible-dose vardenafil in a community-based population of men affected by erectile dysfunction: a 12-week open-label, multicenter trial. <i>Journal of Sexual Medicine</i> , <b>2005</b> , 2, 842-7	1.1	13
63	Patient and partner satisfaction with the Mentor Alpha-1 inflatable penile prosthesis. <i>Scandinavian Journal of Urology and Nephrology</i> , <b>2005</b> , 39, 66-8		11
62	Sildenafil: efficacy, safety, tolerability and mechanism of action in treating erectile dysfunction. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2005</b> , 1, 283-93	5.5	34
61	Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. <i>Urology</i> , <b>2005</b> , 65, 755-9	1.6	35
60	A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?. <i>Drugs</i> , <b>2005</b> , 65, 1621-50	12.1	133
59	Treatment for erectile dysfunction based on patient-reported outcomes: to every man the PDE5 inhibitor that he finds superior. <i>Drugs</i> , <b>2005</b> , 65, 2245-51	12.1	24
58	Vardenafil rescue rates of sildenafil nonresponders: objective assessment of 327 patients with erectile dysfunction. <i>Urology</i> , <b>2006</b> , 68, 397-401	1.6	12

57	Management of sildenafil treatment failures. <i>Current Opinion in Urology</i> , <b>2006</b> , 16, 449-59	2.8	33
56	Salvage of sildenafil failures with cabergoline: a randomized, double-blind, placebo-controlled study. <i>International Journal of Impotence Research</i> , <b>2006</b> , 18, 550-8	2.3	17
55	Salvaging the oral treatment failure patient. <i>Current Sexual Health Reports</i> , <b>2006</b> , 3, 20-24	1.2	1
54	Tolerance to the therapeutic effect of tadalafil does not occur during 6 months of treatment: A randomized, double-blind, placebo-controlled study in men with erectile dysfunction. <i>Journal of Sexual Medicine</i> , <b>2006</b> , 3, 504-11	1.1	5
53	Treatment-seeking behavior of erectile dysfunction patients in Europe: Results of the Erectile Dysfunction Observational Study. <i>Journal of Sexual Medicine</i> , <b>2006</b> , 3, 530-40	1.1	32
52	Positive effect of counseling and dose adjustment in patients with erectile dysfunction who failed treatment with sildenafil. <i>European Urology</i> , <b>2006</b> , 50, 134-40	10.2	54
51	Prescribing all phosphodiesterase 5 inhibitors to a patient with erectile dysfunction--a realistic and feasible option in everyday clinical practice--outcomes of a simple treatment regime. <i>European Urology</i> , <b>2006</b> , 49, 900-7; discussion 907	10.2	16
50	Early sildenafil dose optimization and personalized instruction improves the frequency, flexibility, and success of sexual intercourse in men with erectile dysfunction. <i>International Journal of Impotence Research</i> , <b>2007</b> , 19, 154-60	2.3	23
49	Medicalization of women's sexual problems: a different story?. <i>Journal of Sex and Marital Therapy</i> , <b>2007</b> , 33, 443-7	2.7	6
48	How long do patients with erectile dysfunction continue to use sildenafil citrate? Dropout rate from treatment course as outcome in real life. <i>International Journal of Urology</i> , <b>2007</b> , 14, 339-42; discussion 343	2.3	23
47	Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study. <i>International Journal of Clinical Practice</i> , <b>2007</b> , 61, 1850-62	2.9	27
46	Is sex only for the healthy and wealthy?. <i>Journal of Sexual Medicine</i> , <b>2007</b> , 4, 176-182	1.1	18
45	Optimizing response to phosphodiesterase type 5 inhibitors. <i>Current Sexual Health Reports</i> , <b>2007</b> , 4, 1-6	1.2	1
44	Chronic dosing of phosphodiesterase type 5 inhibitors. <i>Current Sexual Health Reports</i> , <b>2008</b> , 5, 65-69	1.2	
43	Efficacy and safety of oral SK3530 for the treatment of erectile dysfunction in Korean men: a multicenter, randomized, double-blind, placebo-controlled, fixed dose, parallel group clinical trial. <i>Asian Journal of Andrology</i> , <b>2008</b> , 10, 791-8	2.8	20
42	Acceptance of and discontinuation rate from erectile dysfunction oral treatment in patients following bilateral nerve-sparing radical prostatectomy. <i>European Urology</i> , <b>2008</b> , 53, 564-70	10.2	70
41	Giving patients with erectile dysfunction the opportunity to try all three available phosphodiesterase type 5 inhibitors contributes to better long-term treatment compliance. <i>Journal of Sexual Medicine</i> , <b>2008</b> , 5, 469-75	1.1	33
40	Therapeutic response after first month of tadalafil treatment predicts 12 months treatment continuation in patients with erectile dysfunction: results from the DETECT study. <i>Journal of Sexual Medicine</i> , <b>2008</b> , 5, 1708-19	1.1	12

39	Does educational status affect a patient's behavior toward erectile dysfunction?. <i>Journal of Sexual Medicine</i> , <b>2008</b> , 5, 1941-8	1.1	15
38	Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. <i>Journal of Sexual Medicine</i> , <b>2008</b> , 5, 2672-80	1.1	60
37	Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. <i>Journal of Urology</i> , <b>2008</b> , 179, 1066-71	2.5	38
36	Effects of pioglitazone on erectile dysfunction in sildenafil poor-responders: a randomized, controlled study. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , <b>2008</b> , 11, 22-31	3.4	18
35	Attrition from an internet-based psychological intervention for erectile dysfunction: who is likely to drop out?. <i>Journal of Sex and Marital Therapy</i> , <b>2009</b> , 35, 391-401	2.7	10
34	Evaluation of patient expectations and treatment satisfaction after 1-year tadalafil therapy for erectile dysfunction: the DETECT study. <i>Journal of Sexual Medicine</i> , <b>2009</b> , 6, 257-67	1.1	13
33	Platelet cyclic guanosine monophosphate as a biomarker of phosphodiesterase type 5 inhibitor efficacy in the treatment of erectile dysfunction: a randomized placebo-controlled study. <i>European Urology</i> , <b>2009</b> , 56, 1067-73	10.2	15
32	Safety and efficacy of sildenafil citrate in treating erectile dysfunction in patients with combat-related post-traumatic stress disorder: a double-blind, randomized and placebo-controlled study. <i>BJU International</i> , <b>2009</b> , 104, 376-83	5.6	15
31	Pharmacogenetics and pharmacogenomics of sexual dysfunction: current status, gaps and potential applications. <i>Pharmacogenomics</i> , <b>2009</b> , 10, 1625-44	2.6	9
30	Phosphodiesterase type 5 inhibitors for the management of erectile dysfunction: preference and adherence to treatment. <i>Current Pharmaceutical Design</i> , <b>2009</b> , 15, 3486-95	3.3	16
29	Motivations for seeking treatment for ED: the woman's perspective. <i>International Journal of Impotence Research</i> , <b>2010</b> , 22, 152-8	2.3	9
28	Persistencia y cambio de tratamiento para la disfunci3n er3ctil en pacientes espa3oles: estudio EDOS. <i>Revista Internacional De Androlog3a</i> , <b>2010</b> , 8, 6-13	0.6	4
27	An open label, randomized, fixed-dose, crossover study comparing efficacy and safety of sildenafil citrate and saffron ( <i>Crocus sativus</i> Linn.) for treating erectile dysfunction in men naïve to treatment. <i>International Journal of Impotence Research</i> , <b>2010</b> , 22, 240-50	2.3	29
26	Association of the T-786C, G894T and 4a/4b polymorphisms of the endothelial nitric oxide synthase gene with vasculogenic erectile dysfunction in Iranian subjects. <i>BJU International</i> , <b>2011</b> , 107, 1994-2001	5.6	32
25	Satisfaction profiles in men using intracavernosal injection therapy. <i>Journal of Sexual Medicine</i> , <b>2011</b> , 8, 512-7	1.1	18
24	Couples' reasons for adherence to, or discontinuation of, PDE type 5 inhibitors for men with erectile dysfunction at 12 to 24-month follow-up after a 6-month free trial. <i>Journal of Sexual Medicine</i> , <b>2012</b> , 9, 857-65	1.1	23
23	Dropout in the treatment of erectile dysfunction with PDE5: a study on predictors and a qualitative analysis of reasons for discontinuation. <i>Journal of Sexual Medicine</i> , <b>2012</b> , 9, 2361-9	1.1	77
22	SOP conservative (medical and mechanical) treatment of erectile dysfunction. <i>Journal of Sexual Medicine</i> , <b>2013</b> , 10, 130-71	1.1	117

21	[Drugs for sexual medicine]. <i>Progres En Urologie</i> , <b>2013</b> , 23, 1299-311	0.9	1
20	Exploring the association between erectile rigidity and treatment adherence with sildenafil. <i>Journal of Sexual Medicine</i> , <b>2013</b> , 10, 1861-6	1.1	5
19	PDE5 inhibitor treatment persistence and adherence in Brazilian men: post-hoc analyses from a 6-month, prospective, observational study. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , <b>2014</b> , 40, 390-9	2	12
18	Reasons and predictive factors for discontinuation of PDE-5 inhibitors despite successful intercourse in erectile dysfunction patients. <i>International Journal of Impotence Research</i> , <b>2014</b> , 26, 87-93 <sup>2,3</sup>	2.3	22
17	Adherence to phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction in long-term users: how do men use the inhibitors?. <i>Sexual Medicine</i> , <b>2014</b> , 2, 96-102	2.7	11
16	Efficacy and safety of mirodenafil for patients with erectile dysfunction: a meta-analysis of three multicenter, randomized, double-blind, placebo-controlled clinical trials. <i>Aging Male</i> , <b>2014</b> , 17, 107-11	2.1	9
15	Intracavernosal Injection for the Diagnosis, Evaluation, and Treatment of Erectile Dysfunction: A Review. <i>Sexual Medicine Reviews</i> , <b>2015</b> , 3, 11-23	5.6	30
14	Can Impaired Elasticity of Aorta Predict the Success of Vardenafil Treatment in Patients with Erectile Dysfunction?. <i>Scientifica</i> , <b>2016</b> , 2016, 4867984	2.6	
13	A review of the efficacy and safety of mirodenafil in the management of erectile dysfunction. <i>Therapeutic Advances in Urology</i> , <b>2016</b> , 8, 100-17	3.2	8
12	First-generation phosphodiesterase type 5 inhibitors dropout: a comprehensive review and meta-analysis. <i>Andrology</i> , <b>2016</b> , 4, 1002-1009	4.2	42
11	How Did Erectile Dysfunction Become "Natural"? A Review of the Critical Social Scientific Literature on Medical Treatment for Male Sexual Dysfunction. <i>Journal of Sex Research</i> , <b>2017</b> , 54, 486-506	4	9
10	Integrating Sexual Partners into Pharmacological Sex Therapy. <b>2017</b> , 453-467		1
9	Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails. <i>Drugs and Aging</i> , <b>2018</b> , 35, 175-187	4.7	12
8	Pharmacology and perspectives in erectile dysfunction in man. <i>Pharmacology &amp; Therapeutics</i> , <b>2020</b> , 208, 107493	13.9	17
7	Men's beliefs about treatment for erectile dysfunction-what influences treatment use? A systematic review. <i>International Journal of Impotence Research</i> , <b>2021</b> , 33, 16-42	2.3	1
6	3 Wetenschappelijk onderzoek naar seksualiteit. <b>2009</b> , 45-67		2
5	Effects of Ginkgo biloba extracts with mirodenafil on the relaxation of corpus cavernosal smooth muscle and the potassium channel activity of corporal smooth muscle cells. <i>Asian Journal of Andrology</i> , <b>2011</b> , 13, 742-6	2.8	12
4	Sexualiteit. <b>2004</b> , 259-298		

3 14 Diagnostiek en interventies. **2009**, 317-337

2 La medicalizzazione della sessualit maschile. *Rivista Di Sessuologia Clinica*, **2018**, 5-35

o

1 Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction. *Patient Preference and Adherence*, **2008**, 2, 149-55

2.4 7